IWWM-12 2024 | Real-world outcomes of autoSCT in patients with WM: a report from LWP EBMT

Obviously because of the rarity of the Waldenstrom’s is a rare subentity of low-grade lymphomas, the information on transplantation is limited as I mentioned earlier. And what we have managed in the EBMT to review the outcomes from patients having transplant from 2010 until 2021. We have 772 patients and it was good to review these outcomes because obviously still we have people even in the modern era with new therapeutic advances that require to have transplant as part of their salvage therapy. And what we have found from these 772 patients is that the five-year overall survival is more than 71%. The progression-free survival is 47% and this means that you have fixed-duration therapy that can rescue your patient and with the way things are progressing, we are giving the opportunity to this group of patients to be able to use different therapy lines that are forthcoming and we have seen a lot of new therapies in the pipeline for Waldenstrom’s as well. Obviously as with any other subgroup of people who undergo autologous stem cell transplantation is the acute toxicity, the reported non-relapse mortality as we call it that is related to toxicity to transplantation from our cohort of 772 patients was 2.6% at one year, 3% at two years and 4% at five years which means that considering that this is high-dose therapy of fixed-duration has acceptable toxicity that for fit transplant-eligible patients still could remain as a therapeutic option at some point in the treatment pathway of Waldenstrom’s.